Literature DB >> 23459111

Complement c5a generation by staphylococcal biofilms.

Ashley E Satorius1, Jacob Szafranski, Derek Pyne, Mahesh Ganesan, Michael J Solomon, Duane W Newton, David M Bortz, John G Younger.   

Abstract

Biofilms production is a central feature of nosocomial infection of catheters and other medical devices used in resuscitation and critical care. However, the very effective biofilm forming pathogen Staphylococcus epidermidis often produces a modest host inflammatory response and few of the signs and symptoms associated with more virulent pathogens. To examine the impact of bacterial biofilm formation on provocation of an innate immune response, we studied the elaboration of the major complement anaphylatoxin C5a by human serum upon contact with S. epidermidis biofilms. Wild-type S. epidermidis and mutants of sarA (a regulatory protein that promotes synthesis of the biofilm-forming polysaccharide intercellular adhesin [PIA]) and icaB (responsible for postexport processing of PIA) were studied. C5a release, as a function of exposed biofilm surface area, was on the order of 1 fmol · cm · s and was dependent on the presence of PIA. Experimental results were used to inform a physiologically based pharmacokinetic model of C5a release by an infected central venous catheter, one of S. epidermidis' primary means of causing human disease. These simulations revealed that the magnitude of C5a release on a superior vena cava catheter completely covered with S. epidermidis would be lower than necessary to alert circulating leukocytes. Combined, the experimental and computational results are highly consistent with clinical observations in which the clinical signs of central line-associated bloodstream infection are often muted in association with this important pathogen.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459111      PMCID: PMC4096246          DOI: 10.1097/SHK.0b013e31828d9324

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  25 in total

1.  Complement activation in emergency department patients with severe sepsis.

Authors:  John G Younger; David O Bracho; Hangyul M Chung-Esaki; Moonseok Lee; Gurpreet K Rana; Ananda Sen; Alan E Jones
Journal:  Acad Emerg Med       Date:  2010-04       Impact factor: 3.451

Review 2.  Staphylococcus epidermidis--the 'accidental' pathogen.

Authors:  Michael Otto
Journal:  Nat Rev Microbiol       Date:  2009-08       Impact factor: 60.633

3.  TLR2 mediates recognition of live Staphylococcus epidermidis and clearance of bacteremia.

Authors:  Tobias Strunk; Melanie R Power Coombs; Andrew J Currie; Peter Richmond; Douglas T Golenbock; Liat Stoler-Barak; Leighanne C Gallington; Michael Otto; David Burgner; Ofer Levy
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

Review 4.  Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Int Immunopharmacol       Date:  2007-08-15       Impact factor: 4.932

5.  Elimination of C5aR prevents intestinal mucosal damage and attenuates neutrophil infiltration in local and remote organs.

Authors:  Da-Zhong Xu; Sergey B Zaets; Ruihua Chen; Qi Lu; Harini Rajan; Xiaoman Yang; John Zhang; Eleonora Feketova; Nancy Bogdan; Edwin A Deitch; Yang Cao
Journal:  Shock       Date:  2009-05       Impact factor: 3.454

Review 6.  Coagulase-negative staphylococcal infections.

Authors:  Kathie L Rogers; Paul D Fey; Mark E Rupp
Journal:  Infect Dis Clin North Am       Date:  2009-03       Impact factor: 5.982

7.  Biofilm formation induces C3a release and protects Staphylococcus epidermidis from IgG and complement deposition and from neutrophil-dependent killing.

Authors:  Sascha A Kristian; Timo A Birkenstock; Ursula Sauder; Dietrich Mack; Friedrich Götz; Regine Landmann
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

Review 8.  Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2.

Authors:  Hyun Lee; Peter L Whitfeld; Charles R Mackay
Journal:  Immunol Cell Biol       Date:  2008-01-29       Impact factor: 5.126

9.  Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach.

Authors:  Yanfei Wang; Xiaoping Ao; Huy Vuong; Meghana Konanur; Fred R Miller; Steve Goodison; David M Lubman
Journal:  J Proteome Res       Date:  2008-08-27       Impact factor: 4.466

10.  The priming effect of C5a on monocytes is predominantly mediated by the p38 MAPK pathway.

Authors:  Valérie Schaeffer; Joseph Cuschieri; Iris Garcia; Megan Knoll; Jens Billgren; Sandra Jelacic; Eileen Bulger; Ronald Maier
Journal:  Shock       Date:  2007-06       Impact factor: 3.454

View more
  5 in total

1.  Zinc oxide nanoparticle suspensions and layer-by-layer coatings inhibit staphylococcal growth.

Authors:  Matthew J McGuffie; Jin Hong; Joong Hwan Bahng; Emmanouil Glynos; Peter F Green; Nicholas A Kotov; John G Younger; J Scott VanEpps
Journal:  Nanomedicine       Date:  2015-10-27       Impact factor: 5.307

2.  Thermal Augmentation of Vancomycin Against Staphylococcal Biofilms.

Authors:  Rachael A Sturtevant; Prannda Sharma; Leonid Pavlovsky; Elizabeth J Stewart; Michael J Solomon; John G Younger
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

Review 3.  Pathogenic Mechanisms and Host Interactions in Staphylococcus epidermidis Device-Related Infection.

Authors:  Marina Sabaté Brescó; Llinos G Harris; Keith Thompson; Barbara Stanic; Mario Morgenstern; Liam O'Mahony; R Geoff Richards; T Fintan Moriarty
Journal:  Front Microbiol       Date:  2017-08-02       Impact factor: 5.640

Review 4.  Beyond sepsis: Staphylococcus epidermidis is an underestimated but significant contributor to neonatal morbidity.

Authors:  Ying Dong; Christian P Speer; Kirsten Glaser
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882

Review 5.  Nanomaterials for alternative antibacterial therapy.

Authors:  Hassan A Hemeg
Journal:  Int J Nanomedicine       Date:  2017-11-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.